Pulmonary artery pressure sensor device performance in patients with atrial fibrillation/flutter

Background: Previous studies have demonstrated that hemodynamic-guided management using implantable pulmonary artery (PA) pressure sensor device reduces heart failure (HF) hospitalizations in patients with HF. It is unclear if atrial fibrillation/flutter (AF) affect the performance of the PA pressure sensor.
Methods: Using the National Readmission Database (NRD) we examined 90-day HF-specific and all-cause readmission in patients with and without AF after PA pressure sensor implantation in the US from 2016 to 2020 in a propensity score matched analysis. Our cohort comprised of adult patients (≥18 years) with an ICD-10 procedural code for PA pressure sensor implantation.          
Results: We included 1515 hospitalizations with PA sensor implantation for 90-day readmission analysis. Among patients implanted with the PA pressure sensor, 17.2% of patients without AF and 16.3% of patients with AF were readmitted primarily for HF within 90-days of discharge (Adjusted OR: 1.07, 95% CI 0.61 – 1.87, p = 0.800). Whereas, 36.3% of patients without AF and 33.9% of patients with AF were readmitted for any cause within 90-days of discharge (Adjusted OR: 0.85, 95% CI 0.53 – 1.37, p = 0.505). In subgroup analysis, there was no difference in HF-specific or all-cause readmission in AF patients with HF with reduced ejection fraction or HF with preserved ejection fraction when compared to those without AF.
Conclusions: Analysis of a large, real-world cohort of HF patients with implantable PA pressure sensor showed that HF-specific and all-cause readmissions at 90 days after PA pressure sensor implantation were comparable between patients with and without AF.